Accelerator mass spectrometry-enabled studies: Current status and future prospects

Bioanalysis

Volumn 2, Issue 3, 2010, Pages 519-541

  Arjomand, Ali ^a  

^a Accium BioSciences Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 1 METHYL 6 PHENYLIMIDAZO[4,5 B]PYRIDINE; ALPHA TOCOPHEROL; AMINOLEVULINIC ACID HEXYL ESTER; ATRAZINE; BETA CAROTENE; CARBON 14; CLARITHROMYCIN; CYANOCOBALAMIN; DAFLON; DIAZEPAM; DIOSMIN; ERYTHROMYCIN; FLUCONAZOLE; FOLIC ACID; IMATINIB; LANCOVUTIDE; MIDAZOLAM; NELFINAVIR; PARACETAMOL; PHENOBARBITAL; PLACEBO; PROPAFENONE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; SUMATRIPTAN; TOLBUTAMIDE; TRIOLEIN; UNINDEXED DRUG; WARFARIN; XANTHOPHYLL; ZIDOVUDINE; NANOMATERIAL;

ACCELERATOR MASS SPECTROMETRY; CHRONIC VEIN INSUFFICIENCY; DIET SUPPLEMENTATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; FRACTIONATION; HEMORRHOID; HUMAN; IN VITRO STUDY; INSTRUMENT VALIDATION; ISOTOPE ANALYSIS; MASS SPECTROMETRY; MATERIALS TESTING; NONHUMAN; NUTRITIONAL SCIENCE; REVIEW; SEPARATION TECHNIQUE; TOXICITY TESTING; ANALYSIS; ANIMAL; CHEMISTRY; DRUG DEVELOPMENT; INSTRUMENTATION; METHODOLOGY; TOXICOLOGY;

ANALYTIC SAMPLE PREPARATION METHODS; ANIMALS; DRUG DISCOVERY; HUMANS; MASS SPECTROMETRY; NANOSTRUCTURES; NUTRITIONAL SCIENCES; TOXICOLOGY;

EID: 79952459611     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.09.188     Document Type: Review

References (155)

1. Frey EF. The earliest medical texts. Clio. Med. 20(1-4), 79-90 (1985).
2. Elmore D, Phillips FM. Accelerator mass spectrometry for measurement of long-lived radioisotopes. Science 236(4801), 543-550 (1987). (Pubitemid 17604482)
3. Turteltaub KW, Felton JS, Gledhill BL et al. Accelerator mass spectrometry in biomedical dosimetry. relationship between low-level exposure and covalent binding of heterocyclic amine carcinogens to DNA. Proc. Natl Acad. Sci. USA 87(14), 5288-5292 (1990). (Pubitemid 20260164)
4. Gilman SD, Gee SJ, Hammock BD et al. Analytical performance of accelerator mass spectrometry and liquid scintillation counting for detection of 14C-labeled atrazine metabolites in human urine. Anal. Chem. 70(16), 3463-3469 (1998).
5. Garner RC, Barker J, Flavell C et al. A validation study comparing accelerator MS and liquid scintillation counting for analysis of 14C-labelled drugs in plasma, urine and faecal extracts. J. Pharm. Biomed. Anal. 24(2), 197-209 (2000).
6. Brown P, Garner C, Glass R, Ridgway C, Hart A. Comparison of accelerator mass spectrometry with gas chromatography for the determination of pesticide residues in individual items in the diets of wild birds and mammals. J. Agric. Food Chem. 52(12), 3693-3701 (2004).
7. Liberman RG, Tannenbaum SR, Hughey BJ et al. An interface for direct analysis of 14C in nonvolatile samples by accelerator mass spectrometry. Anal. Chem. 76(2), 328-334 (2004). (Pubitemid 38090768)
8. Flarakos J, Liberman RG, Tannenbaum SR, Skipper PL. Integration of continuous-flow accelerator mass spectrometry with chromatography and mass-selective detection. Anal. Chem. 80(13), 5079-5085 (2008). (Pubitemid 351956318)
9. Mcintyre CP, Sylva SP, Roberts ML. Gas chromatograph-combustion system for (14) C-accelerator mass spectrometry. Anal. Chem. 81(15), 6 (2009).
10. Zoppi U, Crye J, Song Q, Arjomand A. Performance evaluation of the new AMS system at Accium BioSciences. Radiocarbon 49(1), 10 (2007).
11. Young GC, Corless S, Felgate CC, Colthup PV. Comparison of a 250 KV single-stage accelerator mass spectrometer with a 5 MV tandem accelerator mass spectrometer - fitness for purpose in bioanalysis. Rapid Commun. Mass Spectrom. 22(24), 4035-4042 (2008).
12. Salehpour M, Possnert G, Bryhni H. Subattomole sensitivity in biological accelerator mass spectrometry. Anal. Chem. 80(10), 3515-3521 (2008). (Pubitemid 351705849)
13. Salehpour M, Possnert G, Bryhni H, Palminger-Hallen I, Stahle L. Biological accelerator mass spectrometry at Uppsala University. Appl. Radiat. Isot. 67(3), 495-499 (2009).
14. Salehpour M, Forsgard N, Possnert G. Femtomolar measurements using accelerator mass spectrometry. Rapid Commun. Mass Spectrom. 23(5), 557-563 (2009).
15. Vogel JS, Turteltaub KW, Finkel R, Nelson DE. Accelerator mass spectrometry. Anal. Chem. 67(11), 353A-359A (1995).
16. Brown K, Dingley KH, Turteltaub KW. Accelerator mass spectrometry for biomedical research. Methods Enzymol. 402, 423-443 (2005). (Pubitemid 43053135)
17. Hellborg R, Skog G. Accelerator mass spectrometry. Mass Spectrom. Rev. 27(5), 398-427 (2008).
18. Vogel JS. Rapid production of graphite without contamination for biomedical AMS. Radiocarbon 34, 344-350 (1992).
19. Ognibene TJ, Bench G, Vogel JS, Peaslee GF, Murov S. A high-throughput method for the conversion of CO2 obtained from biochemical samples to graphite in septa-sealed vials for quantification of 14C via accelerator mass spectrometry. Anal. Chem. 75(9), 2192-2196 (2003). (Pubitemid 36542364)
20. Kim SH, Kelly PB, Clifford AJ. Biological/ biomedical accelerator mass spectrometry targets. 2. Physical, morphological, and structural characteristics. Anal. Chem. 80(20), 7661-7669 (2008).
21. Kim SH, Kelly PB, Clifford AJ. Biological/ biomedical accelerator mass spectrometry targets. 1. Optimizing the CO2 reduction step using zinc dust. Anal. Chem. 80(20), 7651-7660 (2008).
22. Kim SH, Kelly PB, Clifford AJ. Accelerator mass spectrometry targets of submilligram carbonaceous samples using the high-throughput Zn reduction method. Anal. Chem. 81(14), 5949-5954 (2009).
23. Salehpour M, Forsgard N, Possnert G. Accelerator mass spectrometry of small biological samples. Rapid Commun. Mass Spectrom. 22(23), 3928-3934 (2008).
24. Buchholz BA, Dueker SR, Lin Y, Clifford AJ, Vogel J. Methods and applications of HPLC-AMS. Nucl. Instrum. Methods Phys. Res. B (192), 5 (2000).
25. Lappin G, Simpson M, Shishikura Y, Garner C. High-performance liquid chromatography accelerator mass spectrometry. Correcting for losses during analysis by internal standardization. Anal. Biochem. 378(1), 93-95 (2008).
26. Dingley KH, Ubick EA, Vogel JS, Haack KW. DNA isolation and sample preparation for quantification of adduct levels by accelerator mass spectrometry. Methods Mol. Biol. 291, 21-27 (2005).
27. Vogel JS, Love AH. Quantitating isotopic molecular labels with accelerator mass spectrometry. Methods Enzymol. 402, 402-422 (2005). (Pubitemid 43053134)
28. Shan G, Huang W, Gee SJ, Buchholz BA, Vogel JS, Hammock BD. Isotope-labeled immunoassays without radiation waste. Proc. Natl Acad. Sci. USA 97(6), 2445-2449 (2000). (Pubitemid 30159190)
29. Hah SS, Mundt JM, Kim HM, Sumbad RA, Turteltaub KW, Henderson PT. Measurement of 7,8-dihydro-8-oxo-2′-deoxyguanosine metabolism in MCF-7 cells at low concentrations using accelerator mass spectrometry. Proc. Natl Acad. Sci. USA 104(27), 11203-11208 (2007). (Pubitemid 47175119)
30. Stites TE, Bailey LB, Scott KC, Toth JP, Fisher WP, Gregory JF 3rd. Kinetic modeling of folate metabolism through use of chronic administration of deuterium-labeled folic acid in men. Am. J. Clin. Nutr. 65(1), 53-60 (1997). (Pubitemid 27020459)
31. Stenstrom K, Leide-Svegborn S, Erlandsson B et al. Application of accelerator mass spectrometry (AMS) for high-sensitivity measurements of 14CO2 in long-term studies of fat metabolism. Appl. Radiat. Isot. 47(4), 417-422 (1996).
32. Clifford AJ, Arjomand A, Dueker SR, Schneider PD, Buchholz BA, Vogel JS. The dynamics of folic acid metabolism in an adult given a small tracer dose of 14C-folic acid. Adv. Exp. Med. Biol. 445, 239-251 (1998).
33. Buchholz BA, Arjomand A, Dueker SR, Schneider PD, Clifford AJ, Vogel JS. Intrinsic erythrocyte labeling and attomole pharmacokinetic tracing of 14C-labeled folic acid with accelerator mass spectrometry. Anal. Biochem. 269(2), 348-352 (1999). (Pubitemid 29201035)
34. Lin Y, Dueker SR, Follett JR et al. Quantitation of in vivo human folate metabolism. Am. J. Clin. Nutr. 80(3), 680-691 (2004). (Pubitemid 41115534)
35. Dueker SR, Lin Y, Buchholz BA et al. Long-term kinetic study of b-carotene, using accelerator mass spectrometry in an adult volunteer. J. Lipid Res. 41(11), 1790-1800 (2000).
36. Hickenbottom SJ, Lemke SL, Dueker SR et al. Dual isotope test for assessing b-carotene cleavage to vitamin A in humans. Eur. J. Nutr. 41(4), 141-147 (2002). (Pubitemid 36056322)
37. Lemke SL, Dueker SR, Follett JR et al. Absorption and retinol equivalence of b-carotene in humans is influenced by dietary vitamin A intake. J. Lipid Res. 44(8), 1591-1600 (2003). (Pubitemid 37279605)
38. Ho CC, DE Moura FF, Kim SH, Clifford AJ. Excentral cleavage of b-carotene in vivo in a healthy man. Am. J. Clin. Nutr. 85(3), 770-777 (2007). (Pubitemid 46393509)
39. Ho CC, De Moura FF, Kim SH, Burri BJ, Clifford AJ. A minute dose of 14C-b-carotene is absorbed and converted to retinoids in humans. J. Nutr. 139(8), 1480-1486 (2009).
40. De Moura FF, Ho CC, Getachew G, Hickenbottom S, Clifford AJ. Kinetics of 14C distribution after tracer dose of 14C-lutein in an adult woman. Lipids 40(10), 1069-1073 (2005).
41. Carkeet C, Dueker SR, Lango J et al. Human vitamin B12 absorption measurement by accelerator mass spectrometry using specifically labeled (14)C-cobalamin. Proc. Natl Acad. Sci. USA 103(15), 5694-5699 (2006).
42. Clifford AJ, De Moura FF, Ho CC et al. A feasibility study quantifying in vivo human a-tocopherol metabolism. Am. J. Clin. Nutr. 84(6), 1430-1441 (2006). (Pubitemid 44912828)
43. Garner RC, Lightfoot TJ, Cupid BC et al. Comparative biotransformation studies of MeIQx and PhIP in animal models and humans. Cancer Lett. 143(2), 161-165 (1999). (Pubitemid 29392950)
44. Dingley KH, Curtis KD, Nowell S, Felton JS, Lang NP, Turteltaub KW. DNA and protein adduct formation in the colon and blood of humans after exposure to a dietary-relevant dose of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Cancer Epidemiol. Biomarkers Prev. 8(6), 507-512 (1999). (Pubitemid 29270334)
45. Turteltaub KW, Dingley KH, Curtis KD et al. Macromolecular adduct formation and metabolism of heterocyclic amines in humans and rodents at low doses. Cancer Lett. 143(2), 149-155 (1999). (Pubitemid 29392948)
46. Malfatti MA, Dingley KH, Nowell-Kadlubar S et al. The urinary metabolite profile of the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b] pyridine is predictive of colon DNA adducts after a low-dose exposure in humans. Cancer Res. 66(21), 10541-10547 (2006). (Pubitemid 44810823)
47. Cupid BC, Lightfoot TJ, Russell D et al. The formation of AFB(1)-macromolecular adducts in rats and humans at dietary levels of exposure. Food Chem. Toxicol. 42(4), 559-569 (2004). (Pubitemid 38314826)
48. Mauthe RJ, Dingley KH, Leveson SH et al. Comparison of DNA-adduct and tissue-available dose levels of MeIQx in human and rodent colon following administration of a very low dose. Int. J. Cancer 80(4), 539-545 (1999). (Pubitemid 29047518)
49. Dingley KH, Freeman SP, Nelson DO, Garner RC, Turteltaub KW. Covalent binding of 2-amino-3,8-dimethylimidazo[4,5-f] quinoxaline to albumin and hemoglobin at environmentally relevant doses. Comparison of human subjects and F344 rats. Drug Metab. Dispos. 26(8), 825-828 (1998). (Pubitemid 28376445)
50. Turteltaub KW, Mauthe RJ, Dingley KH et al. MeIQx-DNA adduct formation in rodent and human tissues at low doses. Mutat. Res. 376(1-2), 243-252 (1997). (Pubitemid 27248608)
51. Mauthe RJ, Snyderwine EG, Ghoshal A, Freeman SP, Turteltaub KW. Distribution and metabolism of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PHiP) in female rats and their pups at dietary doses. Carcinogenesis 19(5), 919-924 (1998). (Pubitemid 28376787)
52. Cheng Y, Li HL, Wang HF et al. Inhibition of nicotine-DNA adduct formation in mice by six dietary constituents. Food Chem. Toxicol. 41(7), 1045-1050 (2003). (Pubitemid 36694513)
53. Li H, Cheng Y, Wang H et al. Inhibition of nitrobenzene-induced DNA and hemoglobin adductions by dietary constituents. Appl. Radiat. Isot. 58(3), 291-298 (2003). (Pubitemid 36204026)
54. Rickert DE, Dingley K, Ubick E, Dix KJ, Molina L. Determination of the tissue distribution and excretion by accelerator mass spectrometry of the nonadecapeptide 14C-Moli1901 in beagle dogs after intratracheal instillation. Chem. Biol. Interact. 155(1-2), 55-61 (2005). (Pubitemid 40835989)
55. DeGregorio MW, Dingley KH, Wurz GT, Ubick E, Turteltaub KW. Accelerator mass spectrometry allows for cellular quantification of doxorubicin at femtomolar concentrations. Cancer Chemother. Pharmacol. 57(3), 335-342 (2006).
56. Leide-Svegborn S, Stenstrom K, Olofsson M et al. Biokinetics and radiation doses for carbon-14 urea in adults and children undergoing the Helicobacter pylori breath test. Eur. J. Nucl. Med. 26(6), 573-580 (1999). (Pubitemid 29263627)
57. Gunnarsson M, Leide-Svegborn S, Stenstrom K et al. No radiation protection reasons for restrictions on 14C urea breath tests in children. Br. J. Radiol. 75(900), 982-986 (2002). (Pubitemid 36149763)
58. Combes RD, Berridge T, Connelly J et al. Early microdose drug studies in human volunteers can minimise animal testing. Proceedings of a workshop organised by volunteers in research and testing. Eur. J. Pharm. Sci. 19(1), 1-11 (2003). (Pubitemid 36506932)
59. Lappin G, Garner RC. Big physics, small doses. The use of AMS and PET in human microdosing of development drugs. Nat. Rev. Drug Discov. 2(3), 233-240 (2003). (Pubitemid 37361669)
60. Buchan P. Smarter candidate selection - utilizing microdosing in exploratory clinical studies. Ernst Schering Res. Found Workshop 59, 7-27 (2007).
61. Butz RF, Morelli G. Innovative strategies for early clinical R & D. IDrugs 11(1), 36-41 (2008).
62. Carpenter AP, Pontecorvo MJ, Hefti FF, Skovronsky DM. The use of the exploratory IND in the evaluation and development of 18F-PET radiopharmaceuticals for amyloid imaging in the brain. A review of one company's experience. Q. J. Nucl. Med. Mol. Imaging 53(4), 387-393 (2009).
63. Jacobson-Kram D, Mills G. Leveraging exploratory investigational new drug studies to accelerate drug development. Clin. Cancer Res. 14(12), 3670-3674 (2008).
64. Kummar S, Rubinstein L, Kinders R et al. Phase 0 clinical trials. Conceptions and misconceptions. Cancer J. 14(3), 133-137 (2008).
65. Sarapa N. Exploratory IND. A new regulatory strategy for early clinical drug development in the United States. Ernst Schering Res. Found. Workshop (59), 151-163 (2007).
66. Balani SK, Nagaraja NV, Qian MG et al. Evaluation of microdosing to assess pharmacokinetic linearity in rats using liquid chromatography-tandem mass spectrometry. Drug Metab. Dispos. 34(3), 384-388 (2006). (Pubitemid 43290896)
67. Bauer M, Langer O, Dal-Bianco P et al. A positron emission tomography microdosing study with a potential antiamyloid drug in healthy volunteers and patients with Alzheimer's disease. Clin. Pharmacol. Ther. 80(3), 216-227 (2006). (Pubitemid 44313902)
68. Bauer M, Wagner CC, Langer O. Microdosing studies in humans. The role of positron emission tomography. Drugs RD 9(2), 73-81 (2008). (Pubitemid 351311221)
69. Sandhu P, Vogel JS, Rose MJ et al. Evaluation of microdosing strategies for studies in preclinical drug development. Demonstration of linear pharmacokinetics in dogs of a nucleoside analog over a 50-fold dose range. Drug Metab. Dispos. 32(11), 1254-1259 (2004). (Pubitemid 39410909)
70. Lappin G, Kuhnz W, Jochemsen R et al. Use of microdosing to predict pharmacokinetics at the therapeutic dose. Experience with 5 drugs. Clin. Pharmacol. Ther. 80(3), 203-215 (2006). (Pubitemid 44313903)
71. Vuong L, Ruckle JL, Blood AB et al. Use of accelerator mass spectrometry to measure the pharmacokinetics and peripheral blood mononuclear cell concentrations of zidovudine. J Pharm Sci 97(7), 2833-2843 (2008).
72. Garner C. New paradigm of early clinical research - EUMAPP. Parliament Magazine 238, 1 (2007).
73. Zhou XJ, Garner RC, Nicholson S, Kissling CJ, Mayers D. Microdose pharmacokinetics of IDX899 and IDX989, candidate HIV-1 non-nucleoside reverse transcriptase inhibitors, following oral and intravenous administration in healthy male subjects. J. Clin. Pharmacol. (2009).
74. Young G, Ellis W, Ayrton J, Hussey E, Adamkiewicz B. Accelerator mass spectrometry (AMS). Recent experience of its use in a clinical study and the potential future of the technique. Xenobiotica 31(8-9), 619-632 (2001). (Pubitemid 32826395)
75. Garner RC, Garner JV, Gregory S, Whattam M, Calam A, Leong D. Comparison of the absorption of micronized (Daflon 500 mg) and nonmicronized 14C-diosmin tablets after oral administration to healthy volunteers by accelerator mass spectrometry and liquid scintillation counting. J. Pharm. Sci. 91(1), 32-40 (2002). (Pubitemid 34074465)
76. Boddy AV, Sludden J, Griffin MJ et al. Pharmacokinetic investigation of imatinib using accelerator mass spectrometry in patients with chronic myeloid leukemia. Clin. Cancer Res. 13(14), 4164-4169 (2007). (Pubitemid 47105979)
77. Garner RC, Goris I, Laenen AA et al. Evaluation of accelerator mass spectrometry in a human mass balance and pharmacokinetic study-experience with 14C-labeled (r)-6-[amino(4-chlorophenyl) (1-methyl-1h-imidazol-5-yl)methyl]-4- (3-chlorophenyl)-1-methyl-2(1h)-quinolinone (r115777), a farnesyl transferase inhibitor. Drug Metab. Dispos. 30(7), 823-830 (2002). (Pubitemid 34671095)
78. Sarapa N, Hsyu PH, Lappin G, Garner RC. The application of accelerator mass spectrometry to absolute bioavailability studies in humans. Simultaneous administration of an intravenous microdose of 14C-nelfinavir mesylate solution and oral nelfinavir to healthy volunteers. J. Clin. Pharmacol. 45(10), 1198-1205 (2005). (Pubitemid 41361920)
79. Miyaji Y, Ishizuka T, Kawai K et al. Use of an intravenous microdose of 14C-labeled drug and accelerator mass spectrometry to measure absolute oral bioavailability in dogs; cross-comparison of assay methods by accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry. Drug Metab. Pharmacokinet. 24(2), 130-138 (2009).
80. Klem B, Lappin G, Nicholson S et al. Determination of the bioavailability of [14C]-hexaminolevulinate using accelerator mass spectrometry after intravesical administration to human volunteers. J. Clin. Pharmacol. 46(4), 456-460 (2006).
81. Beumer JH, Garner RC, Cohen MB et al. Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry. Invest. New Drugs 25(4), 327-334 (2007). (Pubitemid 46944849)
82. Prakash C, Shaffer CL, Tremaine LM et al. Application of liquid chromatography-accelerator mass spectrometry (LC-AMS) to evaluate the metabolic profiles of a drug candidate in human urine and plasma. Drug Metab. Lett. 1(3), 226-231 (2007).
83. Lappin G, Garner RC, Meyers T, Powell J, Varley P. Novel use of accelerator mass spectrometry for the quantification of low levels of systemic therapeutic recombinant protein. J. Pharm. Biomed. Anal. 41(4), 1299-1302 (2006). (Pubitemid 43775886)
84. Nakamura T. [Applications of low-abundance-radioisotope measurements with accelerator mass spectrometry to the biomedical sciences]. Tanpakushitsu Kakusan Koso 39(11), 2011-2020 (1994).
85. Kaye B, Garner RC, Mauthe RJ, Freeman SP, Turteltaub KW. A preliminary evaluation of accelerator mass spectrometry in the biomedical field. J. Pharm. Biomed. Anal. 16(3), 541-543 (1997). (Pubitemid 27514399)
86. Barker J, Garner RC. Biomedical applications of accelerator mass spectrometry-isotope measurements at the level of the atom. Rapid Commun. Mass Spectrom. 13(4), 285-293 (1999). (Pubitemid 29101097)
87. Garner RC. Accelerator mass spectrometry in pharmaceutical research and development - a new ultrasensitive analytical method for isotope measurement. Curr. Drug Metab. 1(2), 205-213 (2000).
88. Turteltaub KW, Vogel JS. Bioanalytical applications of accelerator mass spectrometry for pharmaceutical research. Curr. Pharm. Des. 6(10), 991-1007 (2000). (Pubitemid 30439022)
89. Papac DI, Shahrokh Z. Mass spectrometry innovations in drug discovery and development. Pharm Res 18(2), 131-145 (2001). (Pubitemid 32592591)
90. Lappin G, Garner RC. Current perspectives of 14C-isotope measurement in biomedical accelerator mass spectrometry. Anal. Bioanal. Chem. 378(2), 356-364 (2004). (Pubitemid 40890243)
91. White IN, Brown K. Techniques. The application of accelerator mass spectrometry to pharmacology and toxicology. Trends Pharmacol. Sci. 25(8), 442-447 (2004). (Pubitemid 38981561)
92. Lappin G, Garner RC. The use of accelerator mass spectrometry to obtain early human ADME/PK data. Expert Opin. Drug Metab. Toxicol. 1(1), 23-31 (2005).
93. Palmblad M, Buchholz BA, Hillegonds DJ, Vogel JS. Neuroscience and accelerator mass spectrometry. J. Mass Spectrom. 40(2), 154-159 (2005). (Pubitemid 40327255)
94. Vogel JS. Accelerator mass spectrometry for quantitative in vivo tracing. Biotechniques (Suppl.) 25-29 (2005).
95. Brown K, Tompkins EM, White IN. Applications of accelerator mass spectrometry for pharmacological and toxicological research. Mass Spectrom. Rev. 25(1), 127-145 (2006).
96. Lappin G, Stevens L. Biomedical accelerator mass spectrometry. Recent applications in metabolism and pharmacokinetics. Expert Opin. Drug Metab. Toxicol. 4(8), 1021-1033 (2008).
97. Larsson M. Editorial. Accelerator mass spectrometry. Mass Spectrom. Rev. 27(5), 397 (2008).
98. Hah SS. Recent advances in biomedical applications of accelerator mass spectrometry. J. Biomed. Sci. 16, 54 (2009).
99. Gunnarsson M, Stenstrom K, Leide-Svegborn S et al. Biokinetics and radiation dosimetry for patients undergoing a glycerol tri[1-14C] oleate fat malabsorption breath test. Appl. Radiat. Isot. 58(4), 517-526 (2003). (Pubitemid 36369439)
100. Gunnarsson M, Leide-Svegborn S, Stenstrom K et al. Long-term biokinetics and radiation exposure of patients undergoing 14C-glycocholic acid and 14C-xylose breath tests. Cancer Biother. Radiopharm. 22(6), 762-771 (2007).
101. Shapiro SD, Endicott SK, Province MA, Pierce JA, Campbell EJ. Marked longevity of human lung parenchymal elastic fibers deduced from prevalence of D-aspartate and nuclear weapons-related radiocarbon. J. Clin. Invest. 87(5), 1828-1834 (1991).
102. Bergmann O, Bhardwaj RD, Bernard S et al. Evidence for cardiomyocyte renewal in humans. Science 324(5923), 98-102 (2009).
103. Bhardwaj RD, Curtis MA, Spalding KL et al. Neocortical neurogenesis in humans is restricted to development. Proc. Natl Acad. Sci. USA 103(33), 12564-12568 (2006). (Pubitemid 44267298)
104. Spalding KL, Arner E, Westermark PO et al. Dynamics of fat cell turnover in humans. Nature 453(7196), 783-787 (2008). (Pubitemid 351793777)
105. Spalding KL, Buchholz BA, Bergman LE, Druid H, Frisen J. Forensics. Age written in teeth by nuclear tests. Nature 437(7057), 333-334 (2005). (Pubitemid 41613486)
106. Record RD, Hillegonds D, Simmons C et al. In vivo degradation of 14C-labeled small intestinal submucosa (sis) when used for urinary bladder repair. Biomaterials 22(19), 2653-2659 (2001). (Pubitemid 32727840)
107. Gilbert TW, Stewart-Akers AM, Badylak SF. A quantitative method for evaluating the degradation of biologic scaffold materials. Biomaterials 28(2), 147-150 (2007). (Pubitemid 44537385)
108. Li Y, Shawgo RS, Tyler B et al. In vivo release from a drug delivery MEMS device. J. Control Release 100(2), 211-219 (2004). (Pubitemid 39491273)
109. Buchholz BA, Freeman S, Haack K, Vogel J. Tips and traps in the 14C Bio-AMS preparation laboratory. Nucl. Instrum. Methods Phys. Res. B 172, 5 (2000).
110. Hah SS. Determination of protein-ligand interactions using accelerator mass spectrometry. Modified crosslinking assay. Anal. Sci. 25(5), 731-733 (2009).
111. Minamimoto R, Hamabe Y, Miyaoka T et al. Accelerator mass spectrometry analysis of background 14C-concentrations in human blood. Aiming at reference data for further microdosing studies. Ann. Nucl. Med. 22(10), 883-889 (2008).
112. Nelson DE. A new method for carbon isotopic analysis of protein. Science 251(4993), 552-554 (1991). (Pubitemid 21926155)
113. Palmblad M, Bench G, Vogel JS. Mass by energy loss quantitation as a practical submicrogram balance. Anal. Chem. 77(3), 952-953 (2005).
114. Palmblad M, Vogel JS. Quantitation of binding, recovery and desalting efficiency of peptides and proteins in solid phase extraction micropipette tips. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 814(2), 309-313 (2005).
115. Veltkamp AC. Radiochromatography in pharmaceutical and biomedical analysis. J. Chromatogr. 531, 101-129 (1990). (Pubitemid 20324568)
116. Bogen KT, Keating GA, Meissner S, Vogel JS. Initial uptake kinetics in human skin exposed to dilute aqueous trichloroethylene in vitro. J. Expo. Anal. Environ. Epidemiol. 8(2), 253-271 (1998). (Pubitemid 28236477)
117. Turteltaub KW, Vogel JS, Frantz CE, Shen N. Fate and distribution of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in mice at a human dietary equivalent dose. Cancer Res. 52(17), 4682-4687 (1992).
118. Frantz CE, Bangerter C, Fultz E, Mayer KM, Vogel JS, Turteltaub KW. Dose-response studies of MeIQx in rat liver and liver DNA at low doses. Carcinogenesis 16(2), 367-373 (1995).
119. Turteltaub KW, Vogel JS, Frantz C, Felton JS, Mcmanus M. Assessment of the DNA adduction and pharmacokinetics of PHiP and MeIQx in rodents at doses approximating human exposure using the technique of accelerator mass spectrometry (AMS) and 32P-postlabeling. Princess Takamatsu Symp. 23, 93-102 (1995).
120. Creek MR, Mani C, Vogel JS, Turteltaub KW. Tissue distribution and macromolecular binding of extremely low doses of [14C]-benzene in B6C3F1 mice. Carcinogenesis 18(12), 2421-2427 (1997). (Pubitemid 28134658)
121. Martin EA, Carthew P, White IN et al. Investigation of the formation and accumulation of liver DNA adducts in mice chronically exposed to tamoxifen. Carcinogenesis 18(11), 2209-2215 (1997). (Pubitemid 28134750)
122. White IN, Martin EA, Mauthe RJ, Vogel JS, Turteltaub KW, Smith LI. Comparisons of the binding of [14C]radiolabelled tamoxifen or toremifene to rat DNA using accelerator mass spectrometry. Chem. Biol. Interact. 106(2), 149-160 (1997). (Pubitemid 27463416)
123. Garner RC. The role of DNA adducts in chemical carcinogenesis. Mutat. Res. 402(1-2), 67-75 (1998). (Pubitemid 28440260)
124. Buchholz BA, Fultz E, Haack KW et al. HPLC-accelerator MS measurement of atrazine metabolites in human urine after dermal exposure. Anal. Chem. 71(16), 3519-3525 (1999).
125. Kwok ES, Buchholz BA, Vogel JS, Turteltaub KW, Eastmond DA. Dose-dependent binding of ortho-phenylphenol to protein but not DNA in the urinary bladder of male F344 rats. Toxicol. Appl. Pharmacol. 159(1), 18-24 (1999). (Pubitemid 29404757)
126. Lang NP, Nowell S, Malfatti MA et al. In vivo human metabolism of [2-14C]2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PHiP). Cancer Lett. 143(2), 135-138 (1999). (Pubitemid 29392945)
127. Mani C, Freeman S, Nelson DO, Vogel JS, Turteltaub KW. Species and strain comparisons in the macromolecular binding of extremely low doses of [14C]benzene in rodents, using accelerator mass spectrometry. Toxicol. Appl. Pharmacol. 159(2), 83-90 (1999). (Pubitemid 29426579)
128. Goldman R, Day BW, Carver TA, Mauthe RJ, Turteltaub KW, Shields PG. Quantitation of benzo[a]pyrene-DNA adducts by postlabeling with 14C-acetic anhydride and accelerator mass spectrometry. Chem. Biol. Interact. 126(3), 171-183 (2000). (Pubitemid 30336354)
129. Boocock DJ, Brown K, Gibbs AH, Sanchez E, Turteltaub KW, White IN. Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA. Carcinogenesis 23(11), 1897-1901 (2002). (Pubitemid 35355938)
130. Vogel JS, Keating GA 2nd, Buchholz BA. Protein binding of isofluorophate in vivo after coexposure to multiple chemicals. Environ. Health Perspect. 110(Suppl. 6), 1031-1036 (2002). (Pubitemid 36204297)
131. Williams KE, Carver TA, Miranda JJ et al. Attomole detection of in vivo protein targets of benzene in mice. Evidence for a highly reactive metabolite. Mol. Cell. Proteomics 1(11), 885-895 (2002).
132. Li H, Wang H, Sun H, Liu Y, Liu K, Peng S. Binding of nitrobenzene to hepatic DNA and hemoglobin at low doses in mice. Toxicol. Lett. 139(1), 25-32 (2003). (Pubitemid 36197844)
133. Martin EA, Brown K, Gaskell M et al. Tamoxifen DNA damage detected in human endometrium using accelerator mass spectrometry. Cancer Res. 63(23), 8461-8465 (2003). (Pubitemid 37549502)
134. Turteltaub KW, Mani C. Benzene metabolism in rodents at doses relevant to human exposure from urban air. Res. Rep. Health Eff. Inst. (113), 1-26; discussion 27-35 (2003).
135. Mally A, Zepnik H, Wanek P et al. Ochratoxin A. Lack of formation of covalent DNA adducts. Chem. Res. Toxicol. 17(2), 234-242 (2004). (Pubitemid 38252503)
136. Du HF, Xu LH, Wang HF et al. Formation of MTBE-DNA adducts in mice measured with accelerator mass spectrometry. Environ. Toxicol. 20(4), 397-401 (2005). (Pubitemid 41176676)
137. Malfatti MA, Ubick EA, Felton JS. The impact of glucuronidation on the bioactivation and DNA adduction of the cooked-food carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in vivo. Carcinogenesis 26(11), 2019-2028 (2005). (Pubitemid 41631276)
138. Mally A, Dekant W. DNA adduct formation by ochratoxin a. Review of the available evidence. Food Addit. Contam. 22(Suppl. 1), 65-74 (2005). (Pubitemid 44574576)
139. Hillier SM, Marquis JC, Zayas B et al. DNA adducts formed by a novel antitumor agent 11b-dichloro in vitro and in vivo. Mol. Cancer Ther. 5(4), 977-984 (2006). (Pubitemid 43724598)
140. Skipper PL, Trudel LJ, Kensler TW et al. DNA adduct formation by 2,6-dimethyl-, 3,5-dimethyl-, and 3-ethylaniline in vivo in mice. Chem. Res. Toxicol. 19(8), 1086-1090 (2006). (Pubitemid 44384839)
141. Xie Q, Sun H, Liu Y, Ding X, Fu D, Liu K. Adduction of biomacromolecules with acrylamide (AA) in mice at environmental dose levels studied by accelerator mass spectrometry. Toxicol. Lett. 163(2), 101-108 (2006).
142. Brown K, Tompkins EM, Boocock DJ et al. Tamoxifen forms DNA adducts in human colon after administration of a single [14C]-labeled therapeutic dose. Cancer Res. 67(14), 6995-7002 (2007). (Pubitemid 47105548)
143. Hah SS, Sumbad RA, De Vere White RW, Turteltaub KW, Henderson PT. Characterization of oxaliplatin-DNA adduct formation in DNA and differentiation of cancer cell drug sensitivity at microdose concentrations. Chem. Res. Toxicol. 20(12), 1745-1751 (2007).
144. Watanabe K, Liberman RG, Skipper PL, Tannenbaum SR, Guengerich FP. Analysis of DNA adducts formed in vivo in rats and mice from 1,2-dibromoethane, 1,2-dichloroethane, dibromomethane, and dichloromethane using HPLC/accelerator mass spectrometry and relevance to risk estimates. Chem. Res. Toxicol. 20(11), 1594-1600 (2007). (Pubitemid 350275604)
145. Yuan Y, Wang HF, Sun HF et al. Adduction of DNA with MTBE and TBA in mice studied by accelerator mass spectrometry. Environ. Toxicol. 22(6), 630-635 (2007). (Pubitemid 350105975)
146. Coldwell KE, Cutts SM, Ognibene TJ, Henderson PT, Phillips DR. Detection of adriamycin-DNA adducts by accelerator mass spectrometry at clinically relevant adriamycin concentrations. Nucleic Acids Res. 36(16), e100 (2008).
147. Knutson CG, Skipper PL, Liberman RG, Tannenbaum SR, Marnett LJ. Monitoring in vivo metabolism and elimination of the endogenous DNA adduct, M1DG
148. Xie Q, Liu Y, Sun H et al. Inhibition of acrylamide toxicity in mice by three dietary constituents. J. Agric. Food Chem. 56(15), 6054-6060 (2008).
149. Marsden DA, Jones DJ, Britton RG et al. Dose-response relationships for n7-(2-hydroxyethyl)guanine induced by low-dose [14C]ethylene oxide. Evidence for a novel mechanism of endogenous adduct formation. Cancer Res. 69(7), 3052-3059 (2009).
150. Eap CB, Buclin T, Cucchia G et al. Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity. Eur. J. Clin. Pharmacol. 60(4), 237-246 (2004). (Pubitemid 38916442)
151. Beumer JH, Beijnen JH, Schellens JH. Mass balance studies, with a focus on anticancer drugs. Clin. Pharmacokinet. 45(1), 33-58 (2006). (Pubitemid 43145014)
152. Lappin G, Rowland M, Garner RC. The use of isotopes in the determination of absolute bioavailability of drugs in humans. Expert Opin. Drug Metab. Toxicol. 2(3), 419-427 (2006). (Pubitemid 46141407)
153. EMEA. Position Paper on Non-Clinical Safety Studies to Support Clinical Trials with a Single Microdose. June 2004 www.ema.europa.eu/pdfs/human/swp/ 259902en.pdf
154. US FDA. Guidance for Industry, Investigators, and Reviewers - Exploratory IND Studies. January 2006 www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM078933.pdf
155. US FDA. Guidance for Industry - Safety Testing of Drug Metabolites (2008) www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ ucm079266.pdf